Qualigen Therapeutics, Inc.QLGN
| Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Net loss | - | - | - | - | - | - | -21,034,643 |
|---|
| Depreciation and amortization | - | - | - | - | 6,093 | 113,218 | 152,573 |
|---|
| Amortization of right-of-use assets | - | - | - | - | - | 225,059 | 223,030 |
|---|
| Accounts receivable reserves and allowances | - | - | - | - | - | -247,845 | -59,982 |
|---|
| Inventory reserves | - | - | - | - | - | -108,138 | 18,943 |
|---|
| Common stock issued for professional services | - | - | - | - | - | 101,750 | - |
|---|
| Stock-based compensation | - | - | - | 645,823 | 438,248 | 5 | 5 |
|---|
| Fair value of warrant modification for professional services | - | - | - | - | - | - | 67,370 |
|---|
| Goodwill and fixed asset impairment | - | - | - | - | - | - | 4 |
|---|
| Change in fair value of warrant liabilities | - | - | - | - | - | - | -906,345 |
|---|
| Accounts receivable | - | - | - | - | - | -41,250 | -417,708 |
|---|
| Inventory and equipment held for lease | - | - | - | - | - | -111,422 | 637,410 |
|---|
| Prepaid expenses and other assets | - | - | - | 254,122 | - | - | 99,251 |
|---|
| Accounts payable | -344,240 | 1 | 341,211 | 3 | -2,506,885 | 385,455 | -33,397 |
|---|
| Accrued expenses and other current liabilities | - | - | - | - | - | 1 | -76,266 |
|---|
| R&D grant liability | - | - | - | - | - | - | -534,426 |
|---|
| Operating lease liability | - | - | - | - | - | -254,740 | -134,091 |
|---|
| Deferred revenue | - | - | - | - | - | -416,312 | -62,775 |
|---|
| Deferred tax liability | - | - | - | - | - | - | -271,622 |
|---|
| Net cash used in operating activities | - | - | -7,397,912 | -13,332,927 | -14,516,690 | -14,730,742 | -13 |
|---|
| Purchases of property and equipment | 16,999 | 8,063 | 7,678 | 2,008 | 1,589 | 134,471 | 164,684 |
|---|
| Purchases of equipment held for lease | - | - | - | - | - | - | 154,433 |
|---|
| Payments for patents and licenses | - | - | - | - | - | 6,893 | - |
|---|
| Net cash acquired in business combination | - | - | - | - | - | - | 135,354 |
|---|
| Net cash used in investing activities | - | - | -7,678 | -6,970,999 | 7 | -141,364 | -183,763 |
|---|
| Net proceeds from warrant exercises | - | - | - | - | - | 459,476 | 7,173 |
|---|
| Proceeds from issuance of shares and warrants pursuant to Securities Purchase Agreements | - | - | - | - | - | 9 | - |
|---|
| Proceeds from issuance of convertible debt - related party | - | - | - | - | - | - | 3 |
|---|
| Offering costs of Securities Purchase Agreements | 2 | - | 2 | - | - | 706,929 | - |
|---|
| Principal payments on notes payable | - | - | - | - | - | 138,739 | - |
|---|
| Fractional share payments related to the reverse stock split | - | - | - | - | - | - | 505 |
|---|
| Net cash provided by financing activities | - | - | 23 | 5 | 1 | 8 | 3 |
|---|
| Net change in cash and restricted cash | - | - | - | - | -6,112,288 | -6,438,298 | -10,520,787 |
|---|
| Effect of exchange rate changes on cash and restricted cash | - | - | - | - | - | - | 22,639 |
|---|
| Interest | - | - | - | - | - | 1,233 | - |
|---|
| Taxes | - | 80,702 | 800 | 2,233 | 187,095 | 5,133 | 5,571 |
|---|
| Right-of-use assets obtained in exchange for operating lease liabilities | - | - | - | - | - | 1 | - |
|---|
| Fair value of shares issued for cashless warrant exercises | - | - | - | - | - | 764,657 | - |
|---|
| Net transfers to inventory from equipment held for lease | - | - | - | - | - | 1,304 | - |
|---|
| Fair value of warrant modifications pursuant to Securities Purchase Agreements | - | - | - | - | - | - | 9,439 |
|---|
| Fair value of warrant liabilities on date of exercise | - | - | - | - | - | 2 | 858 |
|---|
| Fair value of warrant modifications for business acquisition | - | - | - | - | - | - | 33,543 |
|---|
| Fair value of assets acquired | - | - | - | - | - | - | 6 |
|---|
| Fair value of liabilities assumed, net of goodwill | - | - | - | - | - | - | 2 |
|---|
| Fair value of Alpha Capital/Qualigen warrants repriced due to acquisition | - | - | - | - | - | - | 696 |
|---|
| Fair value of Qualigen prefunded warrant issued in exchange for NanoSynex stock | - | - | - | - | - | - | 2 |
|---|
| Fair value of Qualigen common stock issued in exchange for NanoSynex stock | - | - | - | - | - | - | 2 |
|---|
| Net cash acquired in business combination (Note 3) | - | - | - | - | - | - | 135,354 |
|---|